SCHEMBL2271007

SCHEMBL2271007

COc1ccc(C(=O)Nc2cc(Oc3ccccc3)ccc2C(=O)O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.69
KMT2A Q03164 2/20 0.69
PKM P14618 1/20 0.69
NPSR1 Q6W5P4 1/20 0.69
KCNK2 O95069 1/20 0.62
KCNK10 P57789 1/20 0.62
F10 P00742 2/20 0.61
MAPT P10636 1/20 0.61
SERPINE1 P05121 1/20 0.60
PGR P06401 1/20 0.60
PYGM P11217 1/20 0.58
NR1H4 Q96RI1 1/20 0.57
HPSE Q9Y251 1/20 0.56
TP53 P04637 1/20 0.56
GAA P10253 1/20 0.56
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2272706 0.96 MEN1 (0.67) MEN1KMT2APKMNPSR1KCNK2
SCHEMBL2272040 0.91 PGR (0.69) MEN1KMT2APKMNPSR1KCNK2
SCHEMBL2271588 0.91 SERPINE1 (0.64) MEN1KMT2APKMMAPTSERPINE1
SCHEMBL2271177 0.90 PYGM (0.72) MEN1KMT2APGRPYGMKCNK9
SCHEMBL2275467 0.90 CYP2C9 (0.63) MEN1KMT2APKMNPSR1MAPT
SCHEMBL2276745 0.88 SERPINE1 (0.65) MEN1KMT2AMAPTSERPINE1PYGM
SCHEMBL2270621 0.88 GALK1 (0.68) SERPINE1PYGMNR1H4HPSE
SCHEMBL2289650 0.88 F10 (0.70) MEN1KMT2APKMNPSR1F10
SCHEMBL2935687 0.88 MEN1 (0.69) MEN1KMT2APKMNPSR1KCNK2
SCHEMBL2272774 0.88 KMT2A (0.63) MEN1KMT2APKMNPSR1KCNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.